Skip to content
Open access

Structural MRI signature predicts tau staging in Alzheimer's disease

Jul 2026 · Alzheimer's & Dementia · Vol 18 · 0 citations · 22 references
Medicine

TL;DR

Evidence is provided that multiregion T1‐MRI patterns can inform on tau‐PET burden in AD and may support approximate tau staging when tau‐PET is unavailable, especially in subjects with more advanced tau burden.

Abstract

Tau positron emission tomography (PET) probes Alzheimer's disease (AD) severity via regional tau spread but is not widely available. We tested whether multiregion structural magnetic resonance imaging (MRI) could approximate individual tau burden.

Read PDF

Similar papers

Open access Aug 2026

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.

Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al. · 1 citation
Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · 0 citations
Open access Sep 2026

Identification of MRI-Derived Structural Biomarkers in Female Alzheimer’s Disease Subjects Using CAT12 and Mimics: Effects of Voxel Geometry on Biomarker Estimation

It is suggested that MRI-derived measures of cortical thickness, tissue volumes, BPV, and BPF provide useful structural biomarkers of AD and emphasize the importance of considering voxel geometry and segmentation methodology when evaluating neuroimaging biomarkers.

Devang Nilesh Thakur, Tarun Goswami · 0 citations
Open access Sep 2026

Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240

Abstract INTRODUCTION We compared the association between mild behavioral impairment (MBI) and first‐ versus second‐generation tau‐positron emission tomography (PET) tracers in preclinical and prodromal Alzheimer's disease (AD). METHODS We assessed 110 individuals with head‐to‐head [18F]MK6240 and [18F]Flortaucipir tau...

I. Bizzi, Arthur C. Macedo, Lydia Trudel et al. · 0 citations
Sep 2026

Clinic-based real-world analysis of amyloid PET positivity and MRI markers across subjective cognitive decline, mild cognitive impairment, and early Alzheimer's disease.

BackgroundAlzheimer's disease (AD) is increasingly defined biologically. Amyloid positron emission tomography (PET) is a validated biomarker; however, evidence from truly consecutive, real-world memory-clinic cohorts spanning subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early AD remains limi...

Heii Arai, Satoko Aiba, Hideo Yamamoto et al. · 0 citations
Open access Aug 2026

Amyloid-Tau PET Fusion Reveals Covarying Network Territories Linked to Disease Stage, Cognition, and APOE4 in Alzheimer’s Disease

High-order joint independent component analysis was used to identify fine-grained, data-driven patterns of Amyloid-Tau covariance across individuals, and overlapping abnormality was also associated with cognition across the greatest number of components and showed the strongest overall association with ADAS13.

Bikesh Bimali, Jia-Yu Chen, A. Iraji · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.